Search clinical trials for: stage IV childhood Hodgkin lymphoma

Total 39577 results

Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

Lymphoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

Lymphoma

United States
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Lymphoma, B-Cell

Japan
French Innovative Leukemia Organisation

Terminated

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Lymphoma

France
Columbia University

Completed

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

Sarcoma | Lymphoma | Kidney Cancer | Leukemia | Neurotoxicity | Peripheral Neuropathy

United States
University Hospital, Linkoeping

Unknown

Tibial Nerve Stimulation in Combination With Biofeedback

Fecal Incontinence

Sweden
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Lymphoma | Graft Versus Host Disease

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Lymphoma

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Lymphoma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Plasma Cell Neoplasm | Myeloproliferative Neoplasms

United States
Regeneron Pharmaceuticals
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Regeneron Pharmaceuticals
National Cancer Institute (NCI)

Completed

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Cancer

United States
Regeneron Pharmaceuticals
National Cancer Institute (NCI)

Completed

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Cancer

United States
Regeneron Pharmaceuticals
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
French Innovative Leukemia Organisation
Mundipharma Pte Ltd.; Janssen, LP

Completed

Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma (ManteauRiBVD)

Lymphoma

France
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Nausea and Vomiting

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Lymphoma

United States
Fox Chase Cancer Center
Genentech, Inc.

Withdrawn

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Completed

Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma (FLE09)

Follicular Lymphoma

Italy
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

No longer available

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Secondary Myelofibrosis

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI)

Withdrawn

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Anaplastic Large Cell Lymphoma | AIDS-related Lymphoma | Adult Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Case Comprehensive Cancer Center

Terminated

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Miami

Completed

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Lymphoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Withdrawn

Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer

Sarcoma | Pain | Lymphoma | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Cachexia | Melanoma (Skin)
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Swiss Group for Clinical Cancer Research

Completed

Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma

France, Switzerland, Italy
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Lymphoma

United States
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Lymphoma

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Lymphoma | Small Intestine Cancer

United States
University of South Florida
National Cancer Institute (NCI)

Terminated

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Cancer

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms | Viral Infection

United States
City of Hope Medical Center
National Cancer Institute (NCI); National Institute of Allergy and Infectious...

Completed

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonneoplastic Condition | Myelodysplastic/Myeloproliferative Neoplasms
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

A Standardized Nursing Intervention Protocol for HCT Patients

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Psychosocial Effects of Cancer and Its Treatment | Myelodysplastic/Myeloproliferative Neoplasms | Therapy-related Toxicity

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation

Cancer

United States
National Institute on Aging (NIA)
National Cancer Institute (NCI)

Completed

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States

Search clinical trials for: stage IV childhood Hodgkin lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations